| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 235 | 2024 | 5061 | 23.130 |
Why?
|
| Pancreatectomy | 88 | 2024 | 652 | 13.970 |
Why?
|
| Carcinoma, Pancreatic Ductal | 103 | 2024 | 1724 | 12.580 |
Why?
|
| Pancreaticoduodenectomy | 69 | 2023 | 690 | 10.690 |
Why?
|
| Adenocarcinoma | 90 | 2024 | 7789 | 7.480 |
Why?
|
| Neoadjuvant Therapy | 95 | 2024 | 4975 | 6.470 |
Why?
|
| Preoperative Care | 18 | 2021 | 1529 | 3.680 |
Why?
|
| Pancreatic Fistula | 13 | 2023 | 99 | 2.750 |
Why?
|
| Robotic Surgical Procedures | 9 | 2023 | 481 | 2.720 |
Why?
|
| Mesenteric Artery, Superior | 7 | 2022 | 71 | 2.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 51 | 2024 | 15862 | 2.400 |
Why?
|
| Neoplasm Staging | 63 | 2024 | 13658 | 2.200 |
Why?
|
| Common Bile Duct Neoplasms | 13 | 2023 | 145 | 2.180 |
Why?
|
| Mesenteric Veins | 9 | 2020 | 73 | 2.180 |
Why?
|
| Fluorouracil | 27 | 2024 | 1944 | 2.150 |
Why?
|
| Deoxycytidine | 27 | 2023 | 1353 | 2.130 |
Why?
|
| Portal Vein | 12 | 2021 | 355 | 2.120 |
Why?
|
| Humans | 328 | 2024 | 261506 | 2.050 |
Why?
|
| Combined Modality Therapy | 38 | 2023 | 8865 | 1.940 |
Why?
|
| Ampulla of Vater | 11 | 2023 | 155 | 1.870 |
Why?
|
| Chemotherapy, Adjuvant | 32 | 2023 | 3890 | 1.830 |
Why?
|
| Pancreas | 15 | 2023 | 718 | 1.810 |
Why?
|
| Neuroendocrine Tumors | 11 | 2021 | 634 | 1.780 |
Why?
|
| Chemoradiotherapy | 18 | 2022 | 1946 | 1.750 |
Why?
|
| Chemoradiotherapy, Adjuvant | 11 | 2019 | 565 | 1.720 |
Why?
|
| Surgical Oncology | 9 | 2023 | 190 | 1.700 |
Why?
|
| Perioperative Care | 6 | 2024 | 451 | 1.690 |
Why?
|
| Aged | 140 | 2023 | 70117 | 1.670 |
Why?
|
| CA-19-9 Antigen | 12 | 2024 | 144 | 1.660 |
Why?
|
| Exercise Therapy | 5 | 2023 | 288 | 1.530 |
Why?
|
| Retrospective Studies | 101 | 2024 | 37905 | 1.430 |
Why?
|
| Survival Rate | 47 | 2021 | 12221 | 1.400 |
Why?
|
| Aged, 80 and over | 83 | 2023 | 29902 | 1.390 |
Why?
|
| Leucovorin | 15 | 2024 | 332 | 1.370 |
Why?
|
| Middle Aged | 135 | 2023 | 86204 | 1.360 |
Why?
|
| Research Design | 4 | 2024 | 1544 | 1.350 |
Why?
|
| Clinical Trials as Topic | 9 | 2023 | 3719 | 1.330 |
Why?
|
| Prognosis | 72 | 2024 | 21713 | 1.320 |
Why?
|
| Male | 151 | 2023 | 123000 | 1.310 |
Why?
|
| Neoplasm Recurrence, Local | 31 | 2023 | 10035 | 1.310 |
Why?
|
| Quality of Life | 8 | 2023 | 4532 | 1.290 |
Why?
|
| Postoperative Care | 6 | 2021 | 739 | 1.240 |
Why?
|
| Exercise | 6 | 2023 | 1183 | 1.220 |
Why?
|
| Female | 149 | 2023 | 141928 | 1.200 |
Why?
|
| Duodenal Neoplasms | 4 | 2022 | 138 | 1.160 |
Why?
|
| Critical Pathways | 6 | 2024 | 149 | 1.140 |
Why?
|
| Neoplasms | 20 | 2024 | 15193 | 1.140 |
Why?
|
| Kaplan-Meier Estimate | 25 | 2020 | 6207 | 1.070 |
Why?
|
| Postoperative Complications | 20 | 2023 | 5542 | 1.060 |
Why?
|
| Population Surveillance | 3 | 2015 | 627 | 1.030 |
Why?
|
| Adult | 98 | 2023 | 77950 | 0.980 |
Why?
|
| Antineoplastic Agents | 16 | 2022 | 14289 | 0.950 |
Why?
|
| Pancreatic Ducts | 4 | 2018 | 122 | 0.930 |
Why?
|
| General Surgery | 3 | 2022 | 326 | 0.920 |
Why?
|
| Analgesics, Opioid | 12 | 2023 | 1371 | 0.890 |
Why?
|
| Cancer Survivors | 2 | 2020 | 650 | 0.890 |
Why?
|
| Follow-Up Studies | 37 | 2022 | 14889 | 0.860 |
Why?
|
| Treatment Outcome | 54 | 2023 | 32848 | 0.850 |
Why?
|
| Duodenal Diseases | 1 | 2022 | 43 | 0.830 |
Why?
|
| Sarcopenia | 4 | 2021 | 110 | 0.820 |
Why?
|
| Pain, Postoperative | 10 | 2023 | 610 | 0.810 |
Why?
|
| Patient Selection | 8 | 2023 | 2055 | 0.800 |
Why?
|
| Adenoma | 3 | 2022 | 716 | 0.800 |
Why?
|
| Albumins | 4 | 2022 | 258 | 0.800 |
Why?
|
| Vascular Surgical Procedures | 4 | 2021 | 655 | 0.790 |
Why?
|
| Tomography, X-Ray Computed | 24 | 2023 | 7551 | 0.780 |
Why?
|
| Laparoscopy | 10 | 2023 | 1225 | 0.770 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2022 | 94 | 0.770 |
Why?
|
| Walking | 2 | 2019 | 277 | 0.740 |
Why?
|
| Prospective Studies | 26 | 2023 | 12873 | 0.730 |
Why?
|
| Survivorship | 1 | 2020 | 109 | 0.730 |
Why?
|
| Pancreatic Cyst | 3 | 2023 | 107 | 0.720 |
Why?
|
| Surgical Procedures, Operative | 4 | 2021 | 383 | 0.690 |
Why?
|
| Neoplasm Invasiveness | 20 | 2021 | 3981 | 0.680 |
Why?
|
| Hepatic Artery | 3 | 2022 | 240 | 0.680 |
Why?
|
| Luminescent Proteins | 6 | 2014 | 289 | 0.670 |
Why?
|
| Gastrectomy | 5 | 2023 | 451 | 0.670 |
Why?
|
| Celiac Artery | 1 | 2018 | 40 | 0.670 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2019 | 92 | 0.660 |
Why?
|
| Venous Thrombosis | 3 | 2019 | 384 | 0.660 |
Why?
|
| Camptothecin | 6 | 2017 | 517 | 0.660 |
Why?
|
| Fear | 2 | 2017 | 254 | 0.650 |
Why?
|
| Lymphatic Metastasis | 19 | 2023 | 4844 | 0.650 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2022 | 2594 | 0.640 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2022 | 1303 | 0.630 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 164 | 0.620 |
Why?
|
| Streptozocin | 2 | 2018 | 75 | 0.610 |
Why?
|
| Capecitabine | 7 | 2022 | 388 | 0.590 |
Why?
|
| Frailty | 1 | 2019 | 113 | 0.590 |
Why?
|
| Lymph Nodes | 12 | 2023 | 2967 | 0.580 |
Why?
|
| Home Care Services | 1 | 2017 | 92 | 0.580 |
Why?
|
| Gastric Bypass | 3 | 2022 | 81 | 0.580 |
Why?
|
| Paclitaxel | 5 | 2023 | 1996 | 0.570 |
Why?
|
| Videoconferencing | 2 | 2018 | 56 | 0.570 |
Why?
|
| Patient Compliance | 2 | 2019 | 667 | 0.570 |
Why?
|
| Propensity Score | 2 | 2019 | 750 | 0.570 |
Why?
|
| Somatostatin | 1 | 2017 | 114 | 0.570 |
Why?
|
| Social Support | 1 | 2019 | 560 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 5 | 2022 | 2403 | 0.560 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2022 | 665 | 0.560 |
Why?
|
| Surgeons | 5 | 2023 | 519 | 0.540 |
Why?
|
| Hormones | 1 | 2017 | 266 | 0.530 |
Why?
|
| Neoplasm Metastasis | 11 | 2021 | 5112 | 0.520 |
Why?
|
| Hepatectomy | 4 | 2020 | 1011 | 0.520 |
Why?
|
| Recovery of Function | 1 | 2019 | 703 | 0.520 |
Why?
|
| Medical Oncology | 3 | 2023 | 1423 | 0.520 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 598 | 0.520 |
Why?
|
| Telemedicine | 3 | 2022 | 471 | 0.520 |
Why?
|
| Patient Discharge | 8 | 2023 | 661 | 0.510 |
Why?
|
| Multivariate Analysis | 13 | 2021 | 4298 | 0.510 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2016 | 716 | 0.500 |
Why?
|
| Robotics | 3 | 2023 | 359 | 0.500 |
Why?
|
| Disease-Free Survival | 22 | 2020 | 10001 | 0.500 |
Why?
|
| Precision Medicine | 3 | 2022 | 1154 | 0.490 |
Why?
|
| Thrombectomy | 1 | 2015 | 158 | 0.490 |
Why?
|
| Biomarkers, Tumor | 21 | 2024 | 10331 | 0.490 |
Why?
|
| Risk Management | 1 | 2015 | 107 | 0.490 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2021 | 607 | 0.480 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2019 | 2231 | 0.470 |
Why?
|
| Preoperative Period | 3 | 2020 | 344 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.460 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 4892 | 0.460 |
Why?
|
| Blood Transfusion | 6 | 2021 | 583 | 0.460 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 493 | 0.450 |
Why?
|
| Multicenter Studies as Topic | 4 | 2023 | 543 | 0.450 |
Why?
|
| Health Care Costs | 1 | 2018 | 674 | 0.440 |
Why?
|
| Margins of Excision | 4 | 2019 | 285 | 0.440 |
Why?
|
| Lymph Node Excision | 8 | 2023 | 1959 | 0.440 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1350 | 0.430 |
Why?
|
| Survival Analysis | 15 | 2021 | 9180 | 0.430 |
Why?
|
| Body Composition | 5 | 2020 | 595 | 0.430 |
Why?
|
| Time Factors | 20 | 2024 | 12926 | 0.420 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.420 |
Why?
|
| Amylases | 2 | 2023 | 66 | 0.410 |
Why?
|
| Pilot Projects | 6 | 2021 | 2803 | 0.410 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2019 | 1299 | 0.410 |
Why?
|
| Texas | 13 | 2020 | 6311 | 0.400 |
Why?
|
| Exosomes | 3 | 2019 | 253 | 0.400 |
Why?
|
| Multidetector Computed Tomography | 2 | 2012 | 150 | 0.400 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2019 | 262 | 0.400 |
Why?
|
| Drug Prescriptions | 4 | 2022 | 289 | 0.400 |
Why?
|
| Neoplasm, Residual | 5 | 2019 | 1656 | 0.380 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2010 | 103 | 0.380 |
Why?
|
| Hospitalization | 2 | 2024 | 2083 | 0.370 |
Why?
|
| Doxorubicin | 2 | 2018 | 3005 | 0.370 |
Why?
|
| Heterografts | 6 | 2018 | 733 | 0.370 |
Why?
|
| Antigens, Neoplasm | 4 | 2023 | 1506 | 0.370 |
Why?
|
| Proportional Hazards Models | 11 | 2017 | 4988 | 0.370 |
Why?
|
| Cohort Studies | 17 | 2023 | 9244 | 0.360 |
Why?
|
| United States | 15 | 2023 | 15433 | 0.360 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2021 | 973 | 0.350 |
Why?
|
| Risk Assessment | 12 | 2019 | 6869 | 0.350 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 294 | 0.350 |
Why?
|
| Blood Loss, Surgical | 3 | 2018 | 309 | 0.350 |
Why?
|
| Risk Factors | 21 | 2023 | 17523 | 0.340 |
Why?
|
| Hospital Mortality | 5 | 2021 | 1274 | 0.340 |
Why?
|
| Tumor Burden | 10 | 2018 | 1987 | 0.330 |
Why?
|
| Patient Readmission | 4 | 2018 | 548 | 0.330 |
Why?
|
| Drug Therapy | 2 | 2020 | 205 | 0.330 |
Why?
|
| Neoplasm Transplantation | 6 | 2018 | 1519 | 0.330 |
Why?
|
| Young Adult | 24 | 2020 | 21445 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2019 | 3821 | 0.310 |
Why?
|
| Feasibility Studies | 7 | 2019 | 2292 | 0.310 |
Why?
|
| Neoplasms, Experimental | 3 | 2021 | 750 | 0.310 |
Why?
|
| Tumor Microenvironment | 9 | 2023 | 2864 | 0.300 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 761 | 0.300 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 394 | 0.300 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.290 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 702 | 0.290 |
Why?
|
| Chi-Square Distribution | 6 | 2015 | 1323 | 0.290 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 524 | 0.280 |
Why?
|
| Cisplatin | 5 | 2014 | 2432 | 0.280 |
Why?
|
| Postoperative Period | 3 | 2016 | 665 | 0.270 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2018 | 436 | 0.260 |
Why?
|
| Dissection | 3 | 2016 | 156 | 0.260 |
Why?
|
| Endosonography | 4 | 2015 | 536 | 0.260 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 992 | 0.260 |
Why?
|
| Quality Improvement | 3 | 2020 | 851 | 0.260 |
Why?
|
| Bile Ducts | 2 | 2018 | 113 | 0.260 |
Why?
|
| Neoplasm Grading | 7 | 2018 | 1742 | 0.250 |
Why?
|
| Green Fluorescent Proteins | 4 | 2012 | 694 | 0.250 |
Why?
|
| Patient Care Team | 4 | 2021 | 795 | 0.250 |
Why?
|
| Smad4 Protein | 2 | 2016 | 196 | 0.250 |
Why?
|
| Disease Progression | 10 | 2021 | 6682 | 0.240 |
Why?
|
| Self Report | 2 | 2019 | 756 | 0.240 |
Why?
|
| Pancreatitis, Chronic | 2 | 2022 | 116 | 0.240 |
Why?
|
| Methocarbamol | 1 | 2023 | 2 | 0.240 |
Why?
|
| Spleen | 2 | 2016 | 676 | 0.240 |
Why?
|
| Radiography | 3 | 2020 | 1904 | 0.240 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2021 | 447 | 0.240 |
Why?
|
| Cooperative Behavior | 2 | 2022 | 313 | 0.230 |
Why?
|
| Biliary Tract | 1 | 2023 | 37 | 0.230 |
Why?
|
| Length of Stay | 6 | 2022 | 1900 | 0.230 |
Why?
|
| Inpatients | 4 | 2022 | 678 | 0.230 |
Why?
|
| Carboxylesterase | 3 | 2021 | 33 | 0.220 |
Why?
|
| Survivors | 3 | 2020 | 1031 | 0.220 |
Why?
|
| Registries | 1 | 2010 | 2170 | 0.220 |
Why?
|
| Immunohistochemistry | 11 | 2019 | 7548 | 0.220 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2023 | 275 | 0.220 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2022 | 20 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 945 | 0.210 |
Why?
|
| Intestinal Polyps | 1 | 2022 | 72 | 0.210 |
Why?
|
| Induction Chemotherapy | 4 | 2022 | 669 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 651 | 0.210 |
Why?
|
| Mice | 22 | 2021 | 34495 | 0.210 |
Why?
|
| Cell Line, Tumor | 13 | 2022 | 14551 | 0.210 |
Why?
|
| Transforming Growth Factor beta | 2 | 2019 | 1130 | 0.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 715 | 0.210 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 33 | 0.210 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2022 | 31 | 0.210 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2022 | 59 | 0.210 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2021 | 16 | 0.200 |
Why?
|
| Rectal Neoplasms | 2 | 2022 | 1202 | 0.200 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 671 | 0.200 |
Why?
|
| Mice, Nude | 8 | 2021 | 4307 | 0.200 |
Why?
|
| Colectomy | 1 | 2023 | 288 | 0.200 |
Why?
|
| Cytidine Deaminase | 1 | 2021 | 83 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 907 | 0.200 |
Why?
|
| Extracellular Traps | 1 | 2021 | 25 | 0.200 |
Why?
|
| Learning Curve | 1 | 2021 | 68 | 0.200 |
Why?
|
| Postoperative Hemorrhage | 2 | 2013 | 162 | 0.200 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 5687 | 0.200 |
Why?
|
| Fluorescent Dyes | 2 | 2014 | 459 | 0.200 |
Why?
|
| Hyperglycemia | 1 | 2024 | 333 | 0.190 |
Why?
|
| Abdomen | 2 | 2013 | 332 | 0.190 |
Why?
|
| Models, Animal | 1 | 2003 | 664 | 0.190 |
Why?
|
| Sentinel Lymph Node | 1 | 2023 | 216 | 0.190 |
Why?
|
| Habits | 1 | 2020 | 36 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2017 | 1335 | 0.180 |
Why?
|
| Telomerase | 1 | 2003 | 525 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.180 |
Why?
|
| Gastroparesis | 1 | 2020 | 72 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 600 | 0.180 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 388 | 0.170 |
Why?
|
| Vascular Remodeling | 1 | 2019 | 48 | 0.170 |
Why?
|
| Lumican | 2 | 2016 | 22 | 0.170 |
Why?
|
| Age Factors | 6 | 2018 | 5377 | 0.170 |
Why?
|
| DNA Mismatch Repair | 2 | 2018 | 268 | 0.170 |
Why?
|
| Animals | 24 | 2021 | 59536 | 0.170 |
Why?
|
| Physical Fitness | 1 | 2019 | 122 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 76 | 0.170 |
Why?
|
| Intestinal Neoplasms | 1 | 2020 | 189 | 0.170 |
Why?
|
| Hand Strength | 1 | 2019 | 65 | 0.170 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 4557 | 0.170 |
Why?
|
| Sarcoma | 2 | 2020 | 1725 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 1073 | 0.160 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2020 | 221 | 0.160 |
Why?
|
| Cryoprotective Agents | 1 | 2018 | 11 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.160 |
Why?
|
| BRCA2 Protein | 2 | 2018 | 358 | 0.160 |
Why?
|
| Cadherins | 3 | 2019 | 660 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2019 | 112 | 0.160 |
Why?
|
| Complement System Proteins | 1 | 2019 | 139 | 0.160 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2017 | 9 | 0.160 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2018 | 53 | 0.160 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 335 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2021 | 597 | 0.160 |
Why?
|
| Oncologists | 1 | 2020 | 134 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2013 | 986 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2019 | 383 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 1538 | 0.150 |
Why?
|
| Bilirubin | 2 | 2022 | 221 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 799 | 0.150 |
Why?
|
| Incidence | 8 | 2022 | 5673 | 0.150 |
Why?
|
| Ileostomy | 1 | 2018 | 46 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4314 | 0.150 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 132 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 538 | 0.150 |
Why?
|
| Colonic Neoplasms | 2 | 2023 | 1390 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2018 | 218 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 190 | 0.150 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 108 | 0.150 |
Why?
|
| BRCA1 Protein | 2 | 2018 | 493 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 2 | 2015 | 141 | 0.150 |
Why?
|
| Disease Management | 2 | 2020 | 1052 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 108 | 0.150 |
Why?
|
| Cryopreservation | 1 | 2018 | 175 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2017 | 66 | 0.150 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 167 | 0.150 |
Why?
|
| Neutrophils | 1 | 2021 | 835 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 383 | 0.150 |
Why?
|
| Argininosuccinate Synthase | 1 | 2017 | 54 | 0.150 |
Why?
|
| Stomach Neoplasms | 2 | 2019 | 2278 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2019 | 348 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 2104 | 0.140 |
Why?
|
| Health Personnel | 1 | 2022 | 625 | 0.140 |
Why?
|
| Stents | 2 | 2023 | 1096 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 221 | 0.140 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 237 | 0.140 |
Why?
|
| Motivation | 1 | 2019 | 499 | 0.140 |
Why?
|
| International Cooperation | 1 | 2017 | 323 | 0.140 |
Why?
|
| Reoperation | 4 | 2015 | 1382 | 0.140 |
Why?
|
| Splenic Vein | 1 | 2015 | 17 | 0.140 |
Why?
|
| Insulinoma | 1 | 2016 | 55 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 232 | 0.140 |
Why?
|
| Information Management | 1 | 2015 | 12 | 0.140 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 134 | 0.140 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 1270 | 0.140 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2016 | 76 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 694 | 0.140 |
Why?
|
| Terminology as Topic | 2 | 2015 | 414 | 0.140 |
Why?
|
| Pneumonectomy | 1 | 2021 | 831 | 0.140 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 11538 | 0.140 |
Why?
|
| Splenic Artery | 1 | 2015 | 50 | 0.140 |
Why?
|
| Adolescent | 11 | 2019 | 31252 | 0.130 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 23 | 0.130 |
Why?
|
| Carcinoma, Papillary | 2 | 2016 | 584 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2003 | 1616 | 0.130 |
Why?
|
| Manuals as Topic | 1 | 2015 | 17 | 0.130 |
Why?
|
| Circulating Tumor DNA | 1 | 2018 | 235 | 0.130 |
Why?
|
| Indazoles | 1 | 2017 | 297 | 0.130 |
Why?
|
| Music | 1 | 2015 | 36 | 0.130 |
Why?
|
| SEER Program | 3 | 2016 | 1000 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 363 | 0.130 |
Why?
|
| Professional Role | 1 | 2015 | 78 | 0.130 |
Why?
|
| Melanoma | 3 | 2022 | 5317 | 0.130 |
Why?
|
| Tissue Array Analysis | 5 | 2015 | 760 | 0.130 |
Why?
|
| Organ Size | 1 | 2017 | 690 | 0.130 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 11 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2019 | 636 | 0.130 |
Why?
|
| Medical Staff, Hospital | 1 | 2015 | 118 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 70 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 1054 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2023 | 1863 | 0.130 |
Why?
|
| Health Behavior | 1 | 2019 | 603 | 0.130 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2014 | 38 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 551 | 0.130 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 1085 | 0.130 |
Why?
|
| Operating Rooms | 1 | 2015 | 122 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 245 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 5 | 2014 | 5395 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 199 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2015 | 82 | 0.120 |
Why?
|
| Biopsy | 3 | 2018 | 3443 | 0.120 |
Why?
|
| Salmonella Infections | 1 | 2014 | 40 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.120 |
Why?
|
| Salmonella typhimurium | 1 | 2014 | 70 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Imidazoles | 2 | 2017 | 999 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 4 | 2019 | 651 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 5178 | 0.120 |
Why?
|
| Thrombocytosis | 1 | 2015 | 121 | 0.120 |
Why?
|
| Fibrinolytic Agents | 2 | 2013 | 324 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2016 | 514 | 0.120 |
Why?
|
| Jejunal Neoplasms | 1 | 2013 | 34 | 0.120 |
Why?
|
| Ileal Neoplasms | 1 | 2013 | 47 | 0.120 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2024 | 222 | 0.110 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 170 | 0.110 |
Why?
|
| Developing Countries | 1 | 2015 | 315 | 0.110 |
Why?
|
| Morbidity | 2 | 2014 | 397 | 0.110 |
Why?
|
| Patient Preference | 1 | 2015 | 218 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2017 | 747 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 690 | 0.110 |
Why?
|
| Suture Techniques | 1 | 2015 | 319 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.110 |
Why?
|
| Mesentery | 2 | 2013 | 72 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 1294 | 0.110 |
Why?
|
| ErbB Receptors | 3 | 2018 | 2295 | 0.110 |
Why?
|
| Algorithms | 4 | 2023 | 3890 | 0.110 |
Why?
|
| Lipoma | 1 | 2013 | 89 | 0.110 |
Why?
|
| Cell Proliferation | 6 | 2021 | 7226 | 0.110 |
Why?
|
| Mice, Inbred NOD | 4 | 2018 | 905 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 3578 | 0.110 |
Why?
|
| Biomedical Research | 2 | 2017 | 806 | 0.110 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 752 | 0.110 |
Why?
|
| Giant Cells | 1 | 2012 | 69 | 0.110 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 170 | 0.110 |
Why?
|
| Office Visits | 1 | 2013 | 97 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.110 |
Why?
|
| Markov Chains | 1 | 2013 | 175 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2992 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 280 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 551 | 0.100 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2014 | 172 | 0.100 |
Why?
|
| Water-Electrolyte Balance | 1 | 2012 | 104 | 0.100 |
Why?
|
| Health Resources | 1 | 2013 | 168 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 100 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 598 | 0.100 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2013 | 75 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1331 | 0.100 |
Why?
|
| RNA | 1 | 2017 | 1013 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 275 | 0.100 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2014 | 223 | 0.100 |
Why?
|
| Cell Movement | 2 | 2021 | 2466 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8873 | 0.100 |
Why?
|
| Veins | 1 | 2012 | 157 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1046 | 0.100 |
Why?
|
| Cyclin D1 | 1 | 2014 | 576 | 0.100 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2018 | 168 | 0.100 |
Why?
|
| Forms and Records Control | 1 | 2011 | 27 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 2326 | 0.100 |
Why?
|
| Vascular System Injuries | 1 | 2011 | 52 | 0.100 |
Why?
|
| Phenotype | 3 | 2021 | 6295 | 0.100 |
Why?
|
| Cholecystectomy | 1 | 2011 | 107 | 0.100 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2012 | 214 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2019 | 4804 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2013 | 668 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2023 | 500 | 0.090 |
Why?
|
| Molecular Imaging | 1 | 2012 | 185 | 0.090 |
Why?
|
| Global Health | 1 | 2015 | 657 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2013 | 375 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 462 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2015 | 529 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Drainage | 2 | 2023 | 416 | 0.090 |
Why?
|
| Radiotherapy Dosage | 3 | 2016 | 3842 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 330 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 915 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 1586 | 0.090 |
Why?
|
| Databases, Factual | 4 | 2018 | 2218 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 289 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 487 | 0.090 |
Why?
|
| Mice, SCID | 4 | 2014 | 1869 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 3022 | 0.090 |
Why?
|
| Reference Standards | 1 | 2010 | 339 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 220 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 343 | 0.090 |
Why?
|
| Cell Survival | 2 | 2018 | 3045 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2011 | 301 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 918 | 0.080 |
Why?
|
| Anastomosis, Surgical | 2 | 2022 | 371 | 0.080 |
Why?
|
| Contrast Media | 2 | 2012 | 1472 | 0.080 |
Why?
|
| Logistic Models | 4 | 2016 | 3441 | 0.080 |
Why?
|
| Mitomycin | 1 | 2009 | 208 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2023 | 6100 | 0.080 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 2283 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1021 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 622 | 0.080 |
Why?
|
| Pandemics | 3 | 2022 | 1559 | 0.080 |
Why?
|
| DNA, Neoplasm | 3 | 2021 | 1910 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2015 | 1270 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2010 | 1313 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 4938 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2024 | 1146 | 0.070 |
Why?
|
| Anthropometry | 2 | 2017 | 269 | 0.070 |
Why?
|
| Appendiceal Neoplasms | 1 | 2009 | 234 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3154 | 0.070 |
Why?
|
| Pyrroles | 1 | 2010 | 576 | 0.070 |
Why?
|
| Elective Surgical Procedures | 2 | 2021 | 250 | 0.070 |
Why?
|
| Interprofessional Relations | 2 | 2020 | 213 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 7222 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 4654 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 726 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2008 | 267 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5539 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2016 | 2316 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 527 | 0.060 |
Why?
|
| Neutropenia | 1 | 2009 | 968 | 0.060 |
Why?
|
| Indoles | 1 | 2010 | 1009 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 510 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 1162 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2017 | 756 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2015 | 1375 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1945 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2023 | 68 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 210 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 6009 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2014 | 3536 | 0.060 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2003 | 69 | 0.060 |
Why?
|
| Celecoxib | 1 | 2023 | 200 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2019 | 16273 | 0.060 |
Why?
|
| Child | 4 | 2019 | 29154 | 0.060 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 14 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 6942 | 0.060 |
Why?
|
| Laparotomy | 1 | 2024 | 211 | 0.060 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 205 | 0.050 |
Why?
|
| Insect Vectors | 1 | 2003 | 110 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2023 | 116 | 0.050 |
Why?
|
| Duodenostomy | 1 | 2022 | 2 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2022 | 68 | 0.050 |
Why?
|
| Cell Line | 1 | 2010 | 5114 | 0.050 |
Why?
|
| Pain Management | 2 | 2020 | 668 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2024 | 228 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2003 | 303 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2003 | 471 | 0.050 |
Why?
|
| Duodenum | 1 | 2023 | 149 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 475 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 259 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2021 | 53 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 181 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 2173 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 15179 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 15694 | 0.050 |
Why?
|
| Device Removal | 1 | 2023 | 337 | 0.050 |
Why?
|
| Calibration | 1 | 2022 | 337 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2021 | 67 | 0.050 |
Why?
|
| Neurons | 1 | 2012 | 2287 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 1082 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2022 | 185 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 254 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 661 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 2139 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2020 | 16 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2008 | 1824 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 233 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2020 | 94 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2003 | 621 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 577 | 0.050 |
Why?
|
| Axilla | 1 | 2023 | 902 | 0.050 |
Why?
|
| Signal Transduction | 4 | 2021 | 11965 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 287 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 4143 | 0.050 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 42 | 0.050 |
Why?
|
| Morphine | 1 | 2022 | 308 | 0.050 |
Why?
|
| Recurrence | 1 | 2008 | 4758 | 0.050 |
Why?
|
| Connecticut | 1 | 2019 | 33 | 0.050 |
Why?
|
| Private Sector | 1 | 2019 | 32 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 3472 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2023 | 611 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 50 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 460 | 0.040 |
Why?
|
| Rectum | 1 | 2022 | 467 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 162 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 82 | 0.040 |
Why?
|
| Proteomics | 2 | 2019 | 1380 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2307 | 0.040 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2019 | 51 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2024 | 1244 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 159 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2021 | 289 | 0.040 |
Why?
|
| Sepsis | 2 | 2015 | 652 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 333 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 253 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 1016 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 149 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 187 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 181 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 600 | 0.040 |
Why?
|
| Transfection | 1 | 2003 | 2944 | 0.040 |
Why?
|
| Mycoplasma hyorhinis | 1 | 2017 | 5 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 350 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 47 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 173 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 158 | 0.040 |
Why?
|
| Gammaproteobacteria | 1 | 2017 | 19 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2588 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 259 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1459 | 0.040 |
Why?
|
| Collagen Type VIII | 1 | 2017 | 5 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2017 | 4821 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 7702 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 925 | 0.040 |
Why?
|
| Collagen Type XVIII | 1 | 2017 | 17 | 0.040 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2017 | 32 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2017 | 178 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2017 | 206 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 490 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 95 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 1048 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 77 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2020 | 499 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 92 | 0.040 |
Why?
|
| Medicaid | 1 | 2019 | 279 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2024 | 1549 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 4971 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 153 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2017 | 136 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 783 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 162 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 827 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 226 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2018 | 380 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5159 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 390 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 21 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 30 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 22 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 1415 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 770 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 1391 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 142 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2020 | 1450 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1516 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2015 | 102 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.030 |
Why?
|
| Pain | 1 | 2023 | 1658 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2019 | 576 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 318 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 899 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 611 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 860 | 0.030 |
Why?
|
| Proteome | 1 | 2018 | 561 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 2015 | 124 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 249 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2014 | 132 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 191 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 1643 | 0.030 |
Why?
|
| Role | 1 | 2014 | 48 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 886 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 409 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 598 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 131 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 394 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 785 | 0.030 |
Why?
|
| Models, Biological | 2 | 2014 | 3254 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 281 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2013 | 61 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 277 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 573 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 671 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1688 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1183 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 1020 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2013 | 13 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 2171 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2015 | 6150 | 0.030 |
Why?
|
| Vipoma | 1 | 2013 | 17 | 0.030 |
Why?
|
| Gastrinoma | 1 | 2013 | 25 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 347 | 0.030 |
Why?
|
| Proteins | 1 | 2021 | 1963 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 821 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 2014 | 188 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 251 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 245 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 304 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 257 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 297 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 85 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 2314 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 272 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 193 | 0.030 |
Why?
|
| Nervous System | 1 | 2013 | 165 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 376 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 702 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2014 | 262 | 0.030 |
Why?
|
| Octreotide | 1 | 2013 | 118 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 108 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 938 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2017 | 779 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 5637 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 229 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1165 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 528 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 734 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 3203 | 0.030 |
Why?
|
| Epithelium | 1 | 2014 | 720 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 1399 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2014 | 501 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 226 | 0.030 |
Why?
|
| Elasticity | 1 | 2012 | 156 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 980 | 0.030 |
Why?
|
| Gallbladder Diseases | 1 | 2011 | 43 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 1014 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2012 | 105 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.020 |
Why?
|
| California | 1 | 2011 | 208 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 2012 | 195 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2012 | 272 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 884 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2011 | 246 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.020 |
Why?
|
| Prevalence | 1 | 2018 | 3260 | 0.020 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.020 |
Why?
|
| Palliative Care | 1 | 2022 | 2037 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1363 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 793 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 2961 | 0.020 |
Why?
|
| Heart Atria | 1 | 2012 | 352 | 0.020 |
Why?
|
| Endoscopy | 1 | 2013 | 479 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 197 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2009 | 191 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 627 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 2084 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 3639 | 0.020 |
Why?
|
| Swine | 1 | 2013 | 1541 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 705 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 2884 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2291 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1493 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2054 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3570 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4320 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 1304 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 402 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 4744 | 0.020 |
Why?
|
| Infant | 1 | 2019 | 13310 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 2341 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 2522 | 0.010 |
Why?
|
| Hypertension | 1 | 2012 | 1503 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 3552 | 0.010 |
Why?
|
| Apoptosis | 1 | 2014 | 7591 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5319 | 0.010 |
Why?
|